Provider Alert! Addition of Paxlovid (Pfizer Oral Covid-19 Drug) to Formulary

Provider Alert! Addition of Paxlovid (Pfizer Oral Covid-19 Drug) to Formulary

Date: January 8, 2024

Attention: Providers

Effective date: January 4, 2024

Call to action: Texas Children’s Health Plan (TCHP) would like to let providers know that effective January 4, 2024, the Texas Health and Human Services (HHS) added Paxlovid to the formulary.

Paxlovid (nirmatrelvir co-packaged with ritonavir) is an oral antiviral tablet, is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

How this impacts providers:

Please see below for the list of impacted drugs (of note, the approval is NDC-specific):

MedicationMedication NDCType of ChangeEffective Date
PAXLOVID 150-100 MG DOSE PACK00069531720FORMULARY ADDITIONJanuary 4, 2024
PAXLOVID 300-100 MG DOSE PACK00069532130FORMULARY ADDITIONJanuary 4, 2024

Next step for Providers: Prescribers are encouraged to educate patients about Paxlovid, including the importance of early intervention and adherence to prescribed treatment regimens. For detailed information on Paxlovid, including prescribing information and eligibility criteria, please refer to the drug’s official prescribing information.

If you have any questions, please email TCHP Pharmacy at:

For access to all provider alerts,log into: or

Share this post